Experience the Quality With Free AOCNP Exam Questions That Helps Candidates Pass

Safe oral chemotherapy practice integrates systems-based protocols: standardized order sets with dosing, cycle length, handling instructions, drug–drug interaction checks, and lab parameters; informed consent capturing risks, benefits, and alternatives; structured education with teach-back; adherence assessment; and proactive toxicity monitoring with clear thresholds for dose modifications and urgent evaluation. The APRN is central to designing workflows that leverage interprofessional collaboration (pharmacy, nursing, navigation), define documentation standards, and establish rapid-access pathways for symptom management to prevent ED utilization. Auto-refills without assessment (Option A) are unsafe. Deferring all monitoring to patients (Option C) misses toxicities and undermines quality metrics. Mandating in-person visits for every refill (Option D) can create access barriers; risk-stratified telehealth plus labs is often appropriate. Metrics such as adherence rates, time to toxicity intervention, and unplanned acute care utilization inform continuous improvement and demonstrate program value.

A positive PHQ-9 item 9 warrants immediate follow-up regardless of plan specificity. The APRN should assess ideation intensity, intent, prior attempts, access to means (firearms/medications), substance use, and protective factors. If moderate risk without imminent intent, create a written safety plan (warning signs, coping strategies, contacts, crisis numbers), restrict lethal means, engage supportive persons (with consent), and arrange urgent mental health referral; same-day evaluation is warranted if risk increases or ambiguity persists. Address modifiable drivers (pain, insomnia, anxiety, depression) and consider initiating evidence-based pharmacotherapy or psychotherapy referral. Close follow-up (within days) is essential. Ignoring the result (Option C) or deferring for weeks (Option A) is unsafe. Benzodiazepines alone (Option D) may worsen depression and suicidality risk and are not a primary treatment. Document assessment, plan, and patient education; coordinate with oncology to maintain treatment continuity while prioritizing safety.

Hyperviscosity syndrome from excess circulating IgM causes impaired microcirculatory flow leading to visual changes, neurologic symptoms, and bleeding. The emergency treatment is therapeutic plasma exchange (plasmapheresis), which rapidly reduces IgM levels and viscosity, relieving symptoms within hours. This is a temporizing measure; definitive control requires disease-directed therapy (e.g., BTK inhibitors, rituximab-based regimens), recognizing that rituximab can transiently increase IgM (flare) and sometimes necessitates pre-emptive plasmapheresis. Steroids alone (Option A) will not promptly lower viscosity. Starting targeted therapy (Option C) without immediate viscosity reduction risks clinical deterioration. Observation/fluids (Option D) are inadequate. APRNs should coordinate emergent apheresis access, hemodynamic/neurologic monitoring, and bleeding management, while planning subsequent systemic therapy in collaboration with hematology. Patient education should address symptom recognition and the potential for recurrence, and documentation should note a history of hyperviscosity to trigger early intervention in future flares.

Hepatocellular carcinoma (HCC) risk remains substantial in certain chronic hepatitis B populations even without cirrhosis, including Asian men >40 years and Asian women >50 years, persons with a family history of HCC, and those with high viral activity or other cofactors. Semiannual abdominal ultrasound—with or without alpha-fetoprotein (AFP)—is the recommended surveillance modality, balancing sensitivity, safety, and cost. Six-month intervals align with typical HCC growth kinetics to improve detection at curable stages (resection, ablation, transplant). AFP alone (Option B) has variable sensitivity/specificity and is not sufficient as a sole test. Annual CT (Option D) increases radiation exposure and cost and is not necessary for routine surveillance unless ultrasound quality is poor (e.g., obesity, steatosis), in which case MRI/CT may be substituted per radiology assessment. Forgoing surveillance (Option A) ignores persistent risk in defined HBV subgroups. The APRN should ensure reliable recall systems, address antiviral management with hepatology, counsel on alcohol avoidance and weight control, and document surveillance results with prompt referral for indeterminate nodules per LI-RADS recommendations.

Robust informed consent ensures ethical, legally sound care and supports patient-centered decision-making. Key elements include the diagnosis and treatment intent (curative vs palliative), proposed regimen (agents, schedule), reasonable alternatives (including no treatment), foreseeable risks—including serious toxicities, late effects, fertility/sexual health issues—expected benefits, and practical considerations (duration, monitoring, potential costs/logistics). It must provide space for patient questions and explicitly state the right to decline or withdraw. Obtaining a mere signature (Option A) without substantive content is inadequate. Documenting “discussed” without detail (Option C) fails legal and accreditation standards. Minimizing risks (Option D) undermines autonomy and can erode trust. APRNs should use plain language, teach-back, multilingual materials, and culturally sensitive approaches; document decisional capacity, consent date/time, and participants. Periodic re-consent is appropriate when regimens change. Embedding standardized consent templates and EHR order sets promotes consistency and safety across the infusion system.